180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.
IPO Year: 2017
Exchange: NASDAQ
Website: 180lifesciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/15/2021 | $11.00 | Buy | Maxim Group |
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
3 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
S-3 - 180 Life Sciences Corp. (0001690080) (Filer)
10-K/A - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
10-K/A - 180 Life Sciences Corp. (0001690080) (Filer)
SCHEDULE 13G - 180 Life Sciences Corp. (0001690080) (Subject)
SCHEDULE 13D/A - 180 Life Sciences Corp. (0001690080) (Subject)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
8-K/A - 180 Life Sciences Corp. (0001690080) (Filer)
10-K - 180 Life Sciences Corp. (0001690080) (Filer)
Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve
PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock. The combined effective offering price for each share of common stock and accompanying wa
PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f
PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his
PALO ALTO, CA / ACCESSWIRE / October 31, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the retention of Mr. Vaclav Vincalek as Senior Technology Consultant. An accomplished technologist with a strong record in technical leadership and strategy, Mr. Vincalek has guided numerous software businesses in areas of team development, technology systems architecture, and stakeholder communication.Mr. Vincalek will work closely with management to oversee the onboarding of the recently acquired Gaming Technology Platform. Commencing this integration process marks a significant step forward in the Company's efforts to establish a robust online gaming infrastructur
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.Currently, Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Doc
LAS VEGAS, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Elray Resources Inc. (OTCPK:ELRA) is pleased to announce a significant milestone in the company's growth strategy. Elray has completed the sale of proprietary technology to 180 Life Sciences Corp. (NASDAQ:ATNF), a NASDAQ-listed company in exchange for preferred stock convertible into a 40% stake in ATNF and warrants to purchase 3 million shares of ATNF common stock, the conversion/exercise of which is subject to stockholder approval. The technology stack contained within Elray's technology package will assist ATNF in launching an iGaming Blockchain casino. "This strategic sale and potential future partnership are expected to enhance Elra
PALO ALTO, CA / ACCESSWIRE / October 9, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180"), is pleased to announce that it has received confirmation from Nasdaq that the Company has officially regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. With this important achievement, the Company can now fully focus on developing its newly announced iGaming business, while also continuing to advance its legacy biotechnology programs.As announced on October 3, 2024, 180 will be shifting its strategic focus towards the rapidly growing global iGaming sector. This transition represents a new chapter for the Company as i
Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors. "We are excited to have Omar stepping onto our executive team," said Mr. Blair Jordan, CEO of 180. "His extensive financial expertise, combined with his forward-thinking approach, makes him the ideal CFO to guide us through this exciting chapter of growth and transformation fo
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced topline results from a clinical pharmacology study (the "Study"), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration (FDA) approved drug for epilepsy, Epidiolex. The purpose of the Study was to compa
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00
SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13D/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13D/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)
PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f
PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.Currently, Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Doc
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors. "We are excited to have Omar stepping onto our executive team," said Mr. Blair Jordan, CEO of 180. "His extensive financial expertise, combined with his forward-thinking approach, makes him the ideal CFO to guide us through this exciting chapter of growth and transformation fo
Pam Marrone joins as Chairwoman of the Board of Directors and Johan de Saegher as Independent Board Member Elicit Plant, an agricultural biotechnology company specialized in crops' resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone as Chairwoman of the Board of Directors and Dr. Johan de Saegher as Independent Board Member. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005582/en/Pam Marrone and Johan de Saegher join Elicit Plant's Board of Directors (Photo: Elicit Plant) Pam is a serial entrepreneur bringing over 30 years of leadership experience
PALO ALTO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the appointment of Quan A. Vu to the role of Chief Operating Officer/Chief Business Officer. Mr. Vu is a highly versatile and accomplished strategy, corporate/business development, finance and operations executive with 20 years of "hands-on" biopharma experience. He is known as a consummate dealmaker with a demonstrated history of prospecting, evaluating, structuring and closing transactions th
MENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors ("Board") effective June 15, 2021. Russell Ray was formerly Managing Director and Co-Head of Global Health Care at Credit Suisse First Boston Corporation where he led a 50-person team with offices in Baltimore, Chicago, London, New York and San Francisco focused on providing corporate finance and M&A adv